home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410m.zip
/
M94A2284.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
42 lines
Document 2284
DOCN M94A2284
TI The preparation for AIDS vaccine efficacy trial in India.
DT 9412
AU Rodrigues J; Mehendale S; Shephard M; Quinn T; Divekar A; Brookmeyer R;
Gangakhedkar R; Gokhale M; Bollinger R; National AIDS Research Institute
(ICMR), Pune, India.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):339 (abstract no. PC0290). Unique
Identifier : AIDSLINE ICA10/94370291
AB In 1993, the first longitudinal study of HIV transmission in India was
begun through the Preparation for HIV/Vaccine Efficacy (PAVE) Trials
program of the NIAID. Since the Indian PAVE site began officially in May
1993, 1870 high risk individuals have been screened from 2 STD clinics
in Pune. 388 were HIV positive (20.7%) including 23 (1.2%) that were
dually reactive for HIV-1 & HIV-2 & 4 (0.1%) for HIV-2 alone. Of
screened individuals, 22.2% were female & 77.6% were male 67% women & 3%
men were commercial sex workers. The mean age of participants was 26
years for women & 27 years for men. The age-specific HIV-1
seroprevalence rates for women were 27.7% (ages 14-19), 31.3% (20-24),
34.6% (25-29), 31.2% (30+). The age-specific HIV-1 sevoprevalence rates
for men were 12.8% (age 14-19), 22.1% (20-24), 25.2% (25-29), 17.3%
(30+). 64% women reported no formal education, compared with 15% men.
42% women & 55% men reported a history of genital ulcer disease & 80%
men presented with an active STD. 9% of the women & 2% of the men
reported a history of blood transfusion. Longitudinal follow-up of this
cohort is underway to estimate HIV seroincidence & build the
infrastructure, which may provide the basis for future HIV vaccine
trials. Local community involvement & governmental support are vital in
undertaking HIV vaccine trials.
DE Acquired Immunodeficiency Syndrome/EPIDEMIOLOGY/*PREVENTION &
CONTROL/TRANSMISSION Adolescence Adult AIDS Vaccines/*ADMINISTRATION
& DOSAGE Clinical Trials/*STATISTICS & NUMER DATA *Developing
Countries Female Follow-Up Studies Human HIV
Infections/EPIDEMIOLOGY/*PREVENTION & CONTROL/TRANSMISSION HIV
Seroprevalence/*TRENDS HIV-1/IMMUNOLOGY HIV-2/IMMUNOLOGY
India/EPIDEMIOLOGY Longitudinal Studies Male Risk Factors MEETING
ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).